Global partnering opportunities and challenges of psoriasis and psoriatic arthritis in Latin America: a report from the GRAPPA 2010 annual meeting.
Documenting the disease burden of psoriasis and psoriatic arthritis (PsA) in Central and South America is difficult. The most conclusive data have come from the Iberoamerican Registry of Spondyloarthritis (RESPONDIA), which registered patients with a diagnosis of spondyloarthritis in a multinational, multicenter (Argentina, Brazil, Costa Rica, Chile, Mexico, Peru, Uruguay, Venezuela, Spain, and Portugal) cross-sectional study conducted between 2006 and 2007. Compared with elsewhere in the Western world, patients with PsA from RESPONDIA were older at study visit, at onset of symptoms, and at diagnosis of spondyloarthritis (SpA); had longer mean disease duration from onset of symptoms to diagnosis; and were more likely to have dactylitis, nail involvement, enthesitis, and peripheral arthritis in lower and upper extremities. It is critical to understand the biologic basis, estimate the disease burden, and determine the clinical treatment of PsA in Latin America. The Group for Research and Assessment of Psoriasis and PsA (GRAPPA) has an increasing number of members from this region. In a coordinated effort, GRAPPA, the Latin American Psoriasis and PsA Society (LAPPAS), and the Pan American League of Associations for Rheumatology (PANLAR) are supporting clinician researchers with educational initiatives in Latin America to understand these conditions.
Section of Rheumatology, Louisiana State University HealthSciences Center, New Orleans, Lousiana 70112-2822, USA. lespin1@lsuhsc.edu
Luis R
LR
Espinoza
Sergio M A
SM
Toloza
Rafael
R
Valle-Onate
Philip J
PJ
Mease
D017668:Age of Onset; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000453:epidemiology* / Q000235:genetics; D003430:Cross-Sectional Studies; D006801:Humans; D007843:Latin America / Q000453:epidemiology; D011565:Psoriasis / Q000175:diagnosis / Q000453:epidemiology* / Q000235:genetics